The University of Southampton
University of Southampton Institutional Repository

Associations of a breast cancer polygenic risk score with tumor characteristics and survival

Associations of a breast cancer polygenic risk score with tumor characteristics and survival
Associations of a breast cancer polygenic risk score with tumor characteristics and survival

Purpose: a polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer.

Methods: women with invasive breast cancer were included, 98,397 of European ancestry and 12,920 of Asian ancestry, from the Breast Cancer Association Consortium (BCAC), and 683 women from the European MINDACT trial. Associations between PRS313 and clinicopathologic characteristics, including the 70-gene signature for MINDACT, were evaluated using logistic regression analyses. Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment.

Results: the PRS313 was associated with more favorable tumor characteristics. In BCAC, increasing PRS313 was associated with lower grade, hormone receptor-positive status, and smaller tumor size. In MINDACT, PRS313 was associated with a low risk 70-gene signature. In European women from BCAC, higher PRS313 was associated with better OS and BCSS: hazard ratio (HR) 0.96 (95% CI, 0.94 to 0.97) and 0.96 (95% CI, 0.94 to 0.98), but the association disappeared after adjustment for clinicopathologic characteristics (and treatment): OS HR, 1.01 (95% CI, 0.98 to 1.05) and BCSS HR, 1.02 (95% CI, 0.98 to 1.07). The results in MINDACT and Asian women from BCAC were consistent.

Conclusion: an increased PRS313 is associated with favorable tumor characteristics, but is not independently associated with prognosis. Thus, PRS313 has no role in the clinical management of primary breast cancer at the time of diagnosis. Nevertheless, breast cancer mortality rates will be higher for women with higher PRS313 as increasing PRS313 is associated with an increased risk of disease. This information is crucial for modeling effective stratified screening programs.

1527-7755
1849-1863
Lopes Cardozo, Josephine M.N.
099e2933-d16b-4be1-adad-52b00f620c0d
Andrulis, Irene L.
62d15733-7183-423d-906b-bbe19ea07444
Bojesen, Stig E.
5bb24168-fd30-4780-b852-c3bf591bccff
Dörk, Thilo
b644de98-231c-49da-a152-7e8de797b6b0
Eccles, Diana M.
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Fasching, Peter A.
28905b56-c431-479b-8687-98d5858e04e9
Hooning, Maartje J.
85db16d6-8d10-4520-8c58-e60e20e8a566
Keeman, Renske
48c84d08-b3c0-4819-a726-542278e980a4
Nevanlinna, Heli
dcece308-e659-4de6-86b4-810564826f25
Rutgers, Emiel J.T.
2ae69b5c-ab7c-491a-827f-9950bcacab89
Easton, Douglas F.
386c61f7-8b57-49d9-a0cc-addb10360598
Hall, Per
38291830-47e9-48f8-8f76-dfd990e55fb6
Pharoah, Paul D.P.
247d3a7d-7b0e-4e9a-ab6d-6f0802a82057
van 't Veer, Laura J.
dcde6900-871e-42a9-8a14-2899115583ef
Schmidt, Marjanka K.
ced57cb8-8b44-4563-b910-d4f2cf62784a
Breast Cancer Association Consortium and MINDACT Collaborators
Lopes Cardozo, Josephine M.N.
099e2933-d16b-4be1-adad-52b00f620c0d
Andrulis, Irene L.
62d15733-7183-423d-906b-bbe19ea07444
Bojesen, Stig E.
5bb24168-fd30-4780-b852-c3bf591bccff
Dörk, Thilo
b644de98-231c-49da-a152-7e8de797b6b0
Eccles, Diana M.
5b59bc73-11c9-4cf0-a9d5-7a8e523eee23
Fasching, Peter A.
28905b56-c431-479b-8687-98d5858e04e9
Hooning, Maartje J.
85db16d6-8d10-4520-8c58-e60e20e8a566
Keeman, Renske
48c84d08-b3c0-4819-a726-542278e980a4
Nevanlinna, Heli
dcece308-e659-4de6-86b4-810564826f25
Rutgers, Emiel J.T.
2ae69b5c-ab7c-491a-827f-9950bcacab89
Easton, Douglas F.
386c61f7-8b57-49d9-a0cc-addb10360598
Hall, Per
38291830-47e9-48f8-8f76-dfd990e55fb6
Pharoah, Paul D.P.
247d3a7d-7b0e-4e9a-ab6d-6f0802a82057
van 't Veer, Laura J.
dcde6900-871e-42a9-8a14-2899115583ef
Schmidt, Marjanka K.
ced57cb8-8b44-4563-b910-d4f2cf62784a

Lopes Cardozo, Josephine M.N., Andrulis, Irene L., Bojesen, Stig E., Dörk, Thilo, Eccles, Diana M. and Fasching, Peter A. , Breast Cancer Association Consortium and MINDACT Collaborators (2023) Associations of a breast cancer polygenic risk score with tumor characteristics and survival. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41 (10), 1849-1863. (doi:10.1200/JCO.22.01978).

Record type: Article

Abstract

Purpose: a polygenic risk score (PRS) consisting of 313 common genetic variants (PRS313) is associated with risk of breast cancer and contralateral breast cancer. This study aimed to evaluate the association of the PRS313 with clinicopathologic characteristics of, and survival following, breast cancer.

Methods: women with invasive breast cancer were included, 98,397 of European ancestry and 12,920 of Asian ancestry, from the Breast Cancer Association Consortium (BCAC), and 683 women from the European MINDACT trial. Associations between PRS313 and clinicopathologic characteristics, including the 70-gene signature for MINDACT, were evaluated using logistic regression analyses. Associations of PRS313 (continuous, per standard deviation) with overall survival (OS) and breast cancer-specific survival (BCSS) were evaluated with Cox regression, adjusted for clinicopathologic characteristics and treatment.

Results: the PRS313 was associated with more favorable tumor characteristics. In BCAC, increasing PRS313 was associated with lower grade, hormone receptor-positive status, and smaller tumor size. In MINDACT, PRS313 was associated with a low risk 70-gene signature. In European women from BCAC, higher PRS313 was associated with better OS and BCSS: hazard ratio (HR) 0.96 (95% CI, 0.94 to 0.97) and 0.96 (95% CI, 0.94 to 0.98), but the association disappeared after adjustment for clinicopathologic characteristics (and treatment): OS HR, 1.01 (95% CI, 0.98 to 1.05) and BCSS HR, 1.02 (95% CI, 0.98 to 1.07). The results in MINDACT and Asian women from BCAC were consistent.

Conclusion: an increased PRS313 is associated with favorable tumor characteristics, but is not independently associated with prognosis. Thus, PRS313 has no role in the clinical management of primary breast cancer at the time of diagnosis. Nevertheless, breast cancer mortality rates will be higher for women with higher PRS313 as increasing PRS313 is associated with an increased risk of disease. This information is crucial for modeling effective stratified screening programs.

Text
Manuscript_ERP262_JCO_resub_clean_20221025 - Accepted Manuscript
Download (268kB)

More information

Accepted/In Press date: 16 December 2022
e-pub ahead of print date: 23 January 2023
Published date: 1 April 2023
Additional Information: Publisher Copyright: © 2023 American Society of Clinical Oncology.

Identifiers

Local EPrints ID: 475052
URI: http://eprints.soton.ac.uk/id/eprint/475052
ISSN: 1527-7755
PURE UUID: 814faec2-b0ca-4927-a87f-4b78eef86921
ORCID for Diana M. Eccles: ORCID iD orcid.org/0000-0002-9935-3169

Catalogue record

Date deposited: 09 Mar 2023 18:51
Last modified: 17 Mar 2024 07:40

Export record

Altmetrics

Contributors

Author: Josephine M.N. Lopes Cardozo
Author: Irene L. Andrulis
Author: Stig E. Bojesen
Author: Thilo Dörk
Author: Diana M. Eccles ORCID iD
Author: Peter A. Fasching
Author: Maartje J. Hooning
Author: Renske Keeman
Author: Heli Nevanlinna
Author: Emiel J.T. Rutgers
Author: Douglas F. Easton
Author: Per Hall
Author: Paul D.P. Pharoah
Author: Laura J. van 't Veer
Author: Marjanka K. Schmidt
Corporate Author: Breast Cancer Association Consortium and MINDACT Collaborators

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×